This post was originally published on this site

August continued to show the biotech market’s resilience in the face of the COVID pandemic with one of the biggest venture fund flows for the month ever, and a half a dozen IPOs. Kymera Therapeutics was one of those August IPOs, and as its co-founder I wanted to share a few reflections. Read more.

The post Kymera Debuts On The Public Markets appeared first on Atlas Venture.